Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
BUSINESS
MTPC Royalties Reach 19.5 Billion Yen from Out-Licensed Gilenya
Mitsubishi Tanabe Pharma Corporation (MTPC)’s royalties have been rapidly growing thanks to favorable sales of its multiple sclerosis treatment Gilenya (fingolimod), which was licensed to Novartis AG of Switzerland. Royalties from Gilenya spiked to 19.5 billion yen in FY2012 from…
To read the full story
BUSINESS
- J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
- Biogen Launches Higher-Dose Spinraza in Japan
November 12, 2025
- Meiji Pharma to Set Up Singapore Subsidiary to Drive ASEAN Biz
November 12, 2025
- Alfresa Deepens Tie-Up with China Wholesaler to Support Japan-to-China Licensing
November 12, 2025
- Japan’s Generic, Biosimilar Market Seen Topping 2 Trillion Yen in 2033: Fuji Keizai
November 12, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…